Skip to content

Stigma in drug research holding back new therapies

Malcolm Hopwood

October 10, 2022 DOI: 10.54377/4346-4c8c (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Theoretical or philosophical paper
Topics Cannabis MDMA Psilocybin
Keywords Hallucinogen Mental health Mental illness Drug Stigma botany
Key points Argues that while party drugs like ketamine and psychedelics are being considered for mental health therapies, proper clinical trials should not be abandoned.

Abstract

Therapy is turning to drugs previously known for being illicit party substances. But there’s no reason to abandon proper trials. A range of new therapies for mental illness were previously considered unthinkable — party drugs including ketamine, medicinal cannabis and psychedelics like MDMA, psilocybin and DMT. With mental health disorders a growing cause of disability […]

Explore topics